Sorafenib inhibits liver cancer growth by decreasing MTOR, AKT, and PI3K expression

Journal of B.U.ON.

Volumn 20, Issue 1, 2015, Pages 218-222

  Zhang, Chi Zhi ^a   Wang, Xiao Dong ^a   Wang, Hong Wei ^a   Cai, Yue ^a   Chao, Li Qin ^a  

^a University of Chinese Medicine   (China)

Author keywords

AKT; MTOR; PI3K; Primary hepatic carcinoma; Sorafenib

Indexed keywords

BETA ACTIN; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; MTOR PROTEIN, HUMAN; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STUDENT T TEST; WESTERN BLOTTING; AGONISTS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; GENETICS; LIVER TUMOR; METABOLISM; PATHOLOGY; TIME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOWN-REGULATION; HUMANS; LIVER NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; TOR SERINE-THREONINE KINASES;

EID: 84928698018     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Tsutsui S, Kume M, Era S. Prognostic value of mi- crovessel density in invasive ductal carcinoma of the breast. Breast Cancer 2003;10:312-319.
2. Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004;6:313-319.
3. Hu Pinjin, Liu Xinguang (Eds): Digestive internal medicine. Beijing: People's Medical Press, 2008, p 188.
4. Canoglu A, Gogus C, Beduk Y et al. Microvessel density as a prognostic marker in bladder carcinoma: correlation with tumor grade, stage and prognosis. Int Urol Nephrol 2004;36:401-405.
5. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and an- giogenesis. Cancer Res 2004;64:7099-7109.
6. Wang Hongwei, Zhang Chizhi, Xu Hanlin et al. The experimental study of Acacia extract serum on inhibiting human hepatoma cell SMMC-7721. Chin J Integr Med 2013;23:279-281.
7. Hirsch FR, Lippman SM. Advances in the biology of lung cancer chemoprevention. J Clin Oncol 2005;23:3186-3197.
8. Dai RY, Chen R, Li H. Cross-talk between PI3K/AKT and MEK/ERK pathways mediates endoplasmic reticulum stress-induced cell cycle progression and cell death in human hepatocellular carcinoma cells. Int J Oncol 2009;34:1749-1757.
9. Chang F, Lee JT, Navolanic PM et al. Involvement of PI3K/AKT pathway in cell cycle progression, apoptosis, and neoplastic transformation: A target for cancer chemotherapy. Leukemia 2003;17:590-603.
10. Coffer PJ, Jin J, Woodgett JR. Protein Kinase B(c-AK- t):A multifunctional mediator of phosphatidylin-sitol 3-Kinase activation. Biochem J 1998;335:1-13.
11. Martelli AM, Evangelisti C, Chiarini F et al. The phos- phatidylinositol 3-Kinase/akT/mTOR Signaling network as a therapeutic target in acute myelogenous leukemia patiens. Oncotarget 2010;1:89-103.
12. Dai Zhi, Zhou Jian, Fan Jia. Hepatocellular carcinoma (HCC) and the relevant important molecular pathways. Chin Liver Dis 2010;18:955-957.
13. Kozma SC, Thomas G. Regulation of cell size in growth, development and human disease: PI3K.PK Band S6K. Bioassays 2002;24:65-71.
14. Fu Cuiqin, Wang Qin, Yin Rong et al. The influence of the PI3K/AKT signaling pathway on liver cancer cell growth and adhesion. World Chin Dig Mag 2008;16:1493-1498.
15. Abou-Alfa GK, Schwartz L, Ricc IS et al. Phase II study of BAY 43-9006 in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-4300.
16. Liu L, Cao Y, Chen C et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis and induces tumor cell apoptosis in hepatocellular carci noma model PLC/PRF/5. Cancer Res 2006;66:11851- 11858.
17. Wu Jing, Luo Rongcheng, Zhang Hua et al. Sorafenib combined with arsenic trioxide on inhibition of the liver cancer cell lines. South Med University 2008;28:639-641.
18. Chen Fengsheng, Cui Yanzhi, Luo Rongcheng et al. Sorafenib combined with cisplatin inhibits the growth of HepG2 liver cancer cells: In vitro study. South Med University 2008;28:1684-1687.